108 related articles for article (PubMed ID: 9305416)
1. Effects of a specific CCK-A antagonist, Loxiglumide, on postprandial mood and sleepiness.
Wells AS; Read NW; Fried M; Borovicka J; D'Amato M
J Psychopharmacol; 1997; 11(3):241-6. PubMed ID: 9305416
[TBL] [Abstract][Full Text] [Related]
2. Effect of a low dose of intraduodenal fat on satiety in humans: studies using the type A cholecystokinin receptor antagonist loxiglumide.
Lieverse RJ; Jansen JB; Masclee AA; Rovati LC; Lamers CB
Gut; 1994 Apr; 35(4):501-5. PubMed ID: 8174988
[TBL] [Abstract][Full Text] [Related]
3. Loxiglumide, a CCK-A receptor antagonist, stimulates calorie intake and hunger feelings in humans.
Beglinger C; Degen L; Matzinger D; D'Amato M; Drewe J
Am J Physiol Regul Integr Comp Physiol; 2001 Apr; 280(4):R1149-54. PubMed ID: 11247838
[TBL] [Abstract][Full Text] [Related]
4. Satiety effects of the type A CCK receptor antagonist loxiglumide in lean and obese women.
Lieverse RJ; Masclee AA; Jansen JB; Rovati LC; Lamers CB
Biol Psychiatry; 1995 Mar; 37(5):331-5. PubMed ID: 7748985
[TBL] [Abstract][Full Text] [Related]
5. Effects of loxiglumide on pancreatic exocrine secretion stimulated by meal in conscious dogs.
Ninomiya K; Saito T; Wakatsuki K; Saeki M; Kato T; Edano K; Kasai H; Kimura K; Fujii M
Arzneimittelforschung; 1998 Jan; 48(1):55-7. PubMed ID: 9522033
[TBL] [Abstract][Full Text] [Related]
6. The effect of cholecystokinin antagonism on postprandial lower oesophageal sphincter function in asymptomatic volunteers and patients with reflux disease.
Trudgill NJ; Hussain FN; Moustafa M; Ajjan R; D'Amato M; Riley SA
Aliment Pharmacol Ther; 2001 Sep; 15(9):1357-64. PubMed ID: 11552906
[TBL] [Abstract][Full Text] [Related]
7. Effect of cholecystokinin-A receptor blockade on lipid-induced gastric relaxation in humans.
Mesquita MA; Thompson DG; Troncon LE; D'Amato M; Rovati LC; Barlow J
Am J Physiol; 1997 Jul; 273(1 Pt 1):G118-23. PubMed ID: 9252517
[TBL] [Abstract][Full Text] [Related]
8. Cholecystokinin receptor antagonist loxiglumide modulates plasma levels of gastro-entero-pancreatic hormones in man. Feedback control of cholecystokinin and gastrin secretion.
Schmidt WE; Creutzfeldt W; Höcker M; Nustede R; Choudhury AR; Schleser A; Rovati LC; Fölsch UR
Eur J Clin Invest; 1991 Oct; 21(5):501-11. PubMed ID: 1752290
[TBL] [Abstract][Full Text] [Related]
9. Effect of a cholecystokinin antagonist on meal-stimulated insulin and pancreatic polypeptide release in humans.
Hildebrand P; Ensinck JW; Ketterer S; Delco F; Mossi S; Bangerter U; Beglinger C
J Clin Endocrinol Metab; 1991 May; 72(5):1123-9. PubMed ID: 2022712
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of food intake in response to intestinal lipid is mediated by cholecystokinin in humans.
Matzinger D; Gutzwiller JP; Drewe J; Orban A; Engel R; D'Amato M; Rovati L; Beglinger C
Am J Physiol; 1999 Dec; 277(6):R1718-24. PubMed ID: 10600919
[TBL] [Abstract][Full Text] [Related]
11. Endogenous cholecystokinin in postprandial lower esophageal sphincter function and fundic tone in humans.
Zerbib F; Bruley Des Varannes S; Scarpignato C; Leray V; D'Amato M; Rozé C; Galmiche JP
Am J Physiol; 1998 Dec; 275(6):G1266-73. PubMed ID: 9843762
[TBL] [Abstract][Full Text] [Related]
12. Cholecystokinin in the control of gastric acid and plasma gastrin and somatostatin secretion in healthy subjects and duodenal ulcer patients before and after eradication of Helicobacter pylori.
Konturek JW
J Physiol Pharmacol; 1994 Dec; 45(4 Suppl 1):3-66. PubMed ID: 7787215
[TBL] [Abstract][Full Text] [Related]
13. Role of endogenously released cholecystokinin in determining postprandial insulin levels in man: effects of loxiglumide, a specific cholecystokinin receptor antagonist.
Baum F; Nauck MA; Ebert R; Cantor P; Hoffmann G; Choudhury AR; Schmidt WE; Creutzfeldt W
Digestion; 1992; 53(3-4):189-99. PubMed ID: 1291406
[TBL] [Abstract][Full Text] [Related]
14. Elevation of feed intake in parasite-infected lambs by central administration of a cholecystokinin receptor antagonist.
Dynes RA; Poppi DP; Barrell GK; Sykes AR
Br J Nutr; 1998 Jan; 79(1):47-54. PubMed ID: 9505802
[TBL] [Abstract][Full Text] [Related]
15. Effects of loxiglumide on pancreatic exocrine secretion stimulated by cholecystokinin-8 in conscious dogs.
Ninomiya K; Saito T; Wakatsuki K; Saeki M; Kato T; Kasai H; Kimura K; Fujii M
Arzneimittelforschung; 1998 Jan; 48(1):52-4. PubMed ID: 9522032
[TBL] [Abstract][Full Text] [Related]
16. Physiological role of cholecystokinin on postprandial insulin secretion and gastric meal emptying in man. Studies with the cholecystokinin receptor antagonist loxiglumide.
Fried M; Schwizer W; Beglinger C; Keller U; Jansen JB; Lamers CB
Diabetologia; 1991 Oct; 34(10):721-6. PubMed ID: 1959704
[TBL] [Abstract][Full Text] [Related]
17. Role of CCK(A) receptors in postprandial lower esophageal sphincter function in morbidly obese subjects.
Hirsch DP; Mathus-Vliegen EM; Holloway RH; Fakhry N; D'Amato M; Boeckxstaens GE
Dig Dis Sci; 2002 Nov; 47(11):2531-7. PubMed ID: 12452391
[TBL] [Abstract][Full Text] [Related]
18. Intestinal phase of human antro-pyloro-duodenal motility: cholinergic and CCK-mediated regulation.
Katschinski M; Schirra J; Begliner C; Langbein S; Wank U; D'Amato M; Arnold R
Eur J Clin Invest; 1996 Jul; 26(7):574-83. PubMed ID: 8864420
[TBL] [Abstract][Full Text] [Related]
19. Effect of loxiglumide (CR-1505) on bombesin- and meal-stimulated plasma cholecystokinin in man.
Jansen JB; Jebbink MC; Douglas BR; Lamers CB
Eur J Clin Pharmacol; 1990; 38(4):367-70. PubMed ID: 2344859
[TBL] [Abstract][Full Text] [Related]
20. Effect of a cholecystokinin receptor antagonist (loxiglumide) on gallbladder contractile function in guinea pigs.
Tsubo K; Arai M; Omachi H; Mitamura K
J Gastroenterol; 1996 Aug; 31(4):578-81. PubMed ID: 8844481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
